Nothing Special   »   [go: up one dir, main page]

WO2015110923A3 - Btk inhibitor for the treatment of chronic lymphocytic and small lymphocytic leukemia - Google Patents

Btk inhibitor for the treatment of chronic lymphocytic and small lymphocytic leukemia Download PDF

Info

Publication number
WO2015110923A3
WO2015110923A3 PCT/IB2015/000645 IB2015000645W WO2015110923A3 WO 2015110923 A3 WO2015110923 A3 WO 2015110923A3 IB 2015000645 W IB2015000645 W IB 2015000645W WO 2015110923 A3 WO2015110923 A3 WO 2015110923A3
Authority
WO
WIPO (PCT)
Prior art keywords
btk inhibitor
cll
treatment
sll
lymphocytic leukemia
Prior art date
Application number
PCT/IB2015/000645
Other languages
French (fr)
Other versions
WO2015110923A2 (en
Inventor
Ahmed HAMDY
Wayne Rothbaum
Raquel IZUMI
Brian Lannutti
Todd Covey
Roger ULRICH
Dave Johnson
Tjeerd Barf
Allard Kaptein
Original Assignee
Acerta Pharma B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acerta Pharma B.V. filed Critical Acerta Pharma B.V.
Priority to US15/112,968 priority Critical patent/US10272083B2/en
Priority to TW104115801A priority patent/TW201609099A/en
Priority to PCT/IB2015/002140 priority patent/WO2016116777A1/en
Priority to ARP150101938A priority patent/AR100892A1/en
Priority to TW104120764A priority patent/TW201628620A/en
Publication of WO2015110923A2 publication Critical patent/WO2015110923A2/en
Publication of WO2015110923A3 publication Critical patent/WO2015110923A3/en
Priority to US16/298,094 priority patent/US11090302B2/en
Priority to US17/370,778 priority patent/US11771696B2/en
Priority to US18/451,030 priority patent/US20240180904A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Therapeutic methods of treating chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) are described. In certain embodiments, the invention includes therapeutic methods of treating CLL and SLL using a BTK inhibitor. In certain embodiments, the invention includes therapeutic methods of treating subtypes of CLL and SLL using a BTK inhibitor, including subtypes of CLL in patients sensitive to thrombosis and subtypes of CLL that increase monocytes and NK cells in peripheral blood after treatment with a BTK inhibitor. In certain embodiments, the invention includes therapeutic methods of treating CLL and SLL using a combination of a BTK inhibitor and an anti-CD20 antibody.
PCT/IB2015/000645 2014-01-21 2015-01-21 Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor WO2015110923A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US15/112,968 US10272083B2 (en) 2014-01-21 2015-01-21 Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
TW104115801A TW201609099A (en) 2014-08-11 2015-05-18 Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
PCT/IB2015/002140 WO2016116777A1 (en) 2014-08-11 2015-06-17 Compositions and methods for treatment of chronic lymphocytic leukemia and small lymphocytic leukemia using a btk inhibitor
ARP150101938A AR100892A1 (en) 2014-01-21 2015-06-17 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYT LEUKEMIA THROUGH THE USE OF A BRUTON TIROSIN QUINASA INHIBITOR
TW104120764A TW201628620A (en) 2014-08-11 2015-06-26 Compositions and methods for treatment of chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
US16/298,094 US11090302B2 (en) 2014-01-21 2019-03-11 Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
US17/370,778 US11771696B2 (en) 2014-01-21 2021-07-08 Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
US18/451,030 US20240180904A1 (en) 2014-01-21 2023-08-16 Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201461929742P 2014-01-21 2014-01-21
US61/929,742 2014-01-21
US201461974665P 2014-04-03 2014-04-03
US61/974,665 2014-04-03
US201462035777P 2014-08-11 2014-08-11
US62/035,777 2014-08-11
USPCT/US2014/068938 2014-12-05
US2014068938 2014-12-05

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/112,968 A-371-Of-International US10272083B2 (en) 2014-01-21 2015-01-21 Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
US16/298,094 Continuation US11090302B2 (en) 2014-01-21 2019-03-11 Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor

Publications (2)

Publication Number Publication Date
WO2015110923A2 WO2015110923A2 (en) 2015-07-30
WO2015110923A3 true WO2015110923A3 (en) 2015-11-26

Family

ID=53373499

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/000645 WO2015110923A2 (en) 2014-01-21 2015-01-21 Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor

Country Status (1)

Country Link
WO (1) WO2015110923A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201618783A (en) 2014-08-07 2016-06-01 艾森塔製藥公司 Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on BTK occupancy and BTK resynthesis rate
SI3317281T1 (en) 2015-07-02 2020-08-31 Acerta Pharma B.V. Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo(1,5-a)pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
MA44909A (en) * 2015-09-15 2018-07-25 Acerta Pharma Bv THERAPEUTIC ASSOCIATION OF A CD19 INHIBITOR AND A BTK INHIBITOR
WO2017046746A1 (en) * 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
AU2016337564A1 (en) * 2015-10-15 2018-05-31 Drug Rediscovery Group Ltd Low dose oral dipyridamole compositions and uses thereof
CN108602827B (en) * 2015-11-06 2021-08-20 安塞塔制药公司 Imidazopyrazine inhibitors of Bruton's tyrosine kinase
US20190008869A1 (en) * 2016-01-13 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of an Antifolate and a BTK Inhibitor
CA3030429A1 (en) 2016-07-14 2018-01-18 Mingsight Pharmaceuticals, Inc. Treatment of cancer
CN107384932B (en) * 2016-08-31 2020-10-20 北京天广实生物技术股份有限公司 Anti-human CD20 humanized monoclonal antibody MIL62, preparation method and application thereof
US10899767B2 (en) 2016-10-05 2021-01-26 Hangzhou Solipharma Co., Ltd. Crystal form of ACP-196, preparation method therefor and pharmaceutical composition thereof
CA3046578A1 (en) * 2016-12-21 2018-06-28 Acerta Pharma B.V. Imidazopyrazine inhibitors of bruton's tyrosine kinase
EA037031B1 (en) * 2017-10-06 2021-01-28 Асерта Фарма Б.В. Imidazopyrazine inhibitors of bruton's tyrosine kinase
SG11202012321PA (en) 2018-07-25 2021-02-25 Novartis Ag Nlrp3 inflammasome inhibitors
AR119731A1 (en) 2019-05-17 2022-01-05 Novartis Ag NLRP3 INFLAMASOME INHIBITORS
PE20230855A1 (en) 2020-08-14 2023-05-29 Novartis Ag HETEROARYL-SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153514A2 (en) * 2010-06-03 2011-12-08 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
WO2013010868A1 (en) * 2011-07-19 2013-01-24 Msd Oss B.V. 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors
WO2014130856A2 (en) * 2013-02-21 2014-08-28 Wayne Rothbaum Treatment of skeletal-related disorders
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2015083008A1 (en) * 2013-12-05 2015-06-11 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
ATE135370T1 (en) 1988-12-22 1996-03-15 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
ES2241710T3 (en) 1991-11-25 2005-11-01 Enzon, Inc. PROCEDURE TO PRODUCE MULTIVALENT PROTEINS FROM UNION TO ANTIGEN.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1999054342A1 (en) 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
ATE430580T1 (en) 2001-10-25 2009-05-15 Genentech Inc GLYCOPROTEIN COMPOSITIONS
AU2003236022A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kogyo Co., Ltd. Cells with modified genome
US8529202B2 (en) 2010-10-12 2013-09-10 General Electric Company System and method for turbine compartment ventilation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153514A2 (en) * 2010-06-03 2011-12-08 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
WO2013010868A1 (en) * 2011-07-19 2013-01-24 Msd Oss B.V. 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors
WO2014130856A2 (en) * 2013-02-21 2014-08-28 Wayne Rothbaum Treatment of skeletal-related disorders
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2015083008A1 (en) * 2013-12-05 2015-06-11 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor

Also Published As

Publication number Publication date
WO2015110923A2 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
WO2015110923A3 (en) Btk inhibitor for the treatment of chronic lymphocytic and small lymphocytic leukemia
MX2017011834A (en) Peptidomimetic macrocycles and uses thereof.
MY187540A (en) Compounds active towards bromodomains
WO2014138429A3 (en) Peptidomimetic macrocycles and use thereof in regulating hif1alpha
BR112017005598A2 (en) peptidomimetic macrocycles and their uses
EA201692285A8 (en) EZH2 INHIBITORS FOR TREATING LYMPHOMA
MX2017011486A (en) Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases.
MX2018010640A (en) Glucagon and glp-1 co-agonists for the treatment of obesity.
MX2016015630A (en) Novel compounds.
NZ767902A (en) Methods of treating ulcerative colitis
MX2021010886A (en) Medicaments for slowing parkinson's disease.
DK3808188T1 (en) FISHING FEED AND PROCEDURE FOR SMOLTIFICATION AND PREVENTION OF DESMOLTIFICATION IN SALMONIDAE AND FOR THE PROPHYLAXATION AND TREATMENT OF HALMORAGIC SMOLT SYNDROME (HSS) IN SALMONIDAE
WO2015006753A3 (en) Therapies for diseases caused by arthropod-borne parasites
MX2017003513A (en) Hsp90-targeted inflammation and infection imaging and therapy.
WO2017069288A8 (en) Pharmaceutical composition for use in treating aml and method of treating aml in a subject in need thereof
MX2017005884A (en) Methods of treating ckd using predictors of fluid retention.
IL260373B (en) Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
MX2017013047A (en) Treatment of pain.
SG10201810016XA (en) Methods of treating depression using nmda modulators
EP4342544A3 (en) Enhancing the therapeutic activity of an immune checkpoint inhibitor
AR100734A1 (en) METHOD FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
MX2022006154A (en) Combinations and uses thereof.
MX2017016346A (en) Methods of treatment with taselisib.
MX2016016667A (en) Methods of treating cancer and preventing cancer drug resistance.
IT201700088621A1 (en) Food supplements for use in the treatment of diseases associated with alterations of peripheral nerve trophism.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15728137

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 15112968

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15728137

Country of ref document: EP

Kind code of ref document: A2